Trademark Overview
On Wednesday, March 20, 2024, a trademark application was filed for IMPERA MEDICINES with the United States Patent and Trademark Office. The USPTO has given the IMPERA MEDICINES trademark a serial number of 98459161. The federal status of this trademark filing is EXAMINERS AMENDMENT - MAILED as of Friday, October 4, 2024. This trademark is owned by Impera Medicines, LP. The IMPERA MEDICINES trademark is filed in the Advertising, Business and Retail Services, Pharmaceutical Products, Insurance & Financial Services, and Computer & Software Services & Scientific Services categories with the following description:
medicinal preparations for the treatment of infectious diseases and for use in oncology; biological preparations for the treatment of cancer; anti-cancer preparations; medicinal preparations for the treatment of cardiometabolic diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cardiometabolic diseases; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, cardiometabolic, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
investment consultancy for biotechnology companies; investment management for biotechnology companies; financial services, namely, investment management and advisory services in the field of biotechnology; intellectual property venture fund management services in the field of biotechnology
Business consultancy in the field of biotechnology; professional business consulting for biotechnology companies; business consulting, business management and providing information in the biotechnology business field; business services, namely, assisting the owners of intellectual property and intangible assets in the field of biotechnology in finding investors
research and development services in the fields of immunology and oncology; research and development services in the field of cardiometabolic diseases; medical research in the field of oncology; medical research in the field of immunology; medical research in the field of cardiometabolic diseases; research, development, engineering and testing services in the field of pharmaceuticals for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, cardiometabolic, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
